Literature DB >> 15304674

Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands).

J Sautner1, I Andel, B Rintelen, B F Leeb.   

Abstract

OBJECTIVES: The Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (SACRAH) is a self-administered questionnaire assessing functional status, stiffness and pain in patients suffering from hand osteoarthritis (HOA) as well as rheumatoid arthritis (RA) of the hand. It consists of 23 questions in three domains, to be answered on 100 mm visual analogue scales (VAS). Our goal was to shorten the original SACRAH by elimination of redundant questions in order to make it easier to use for patients and physicians.
METHODS: Following an arbitrary procedure employing high intervariable correlations, redundant questions were eventually eliminated. To validate the shortened version, 60 patients with HOA, recruited at four rheumatological centres in Austria, completed the original SACRAH as well as the shortened version. Fifty-five patients suffering from RA of the hands treated at the Second Department of Medicine, Humanis Klinikum Stockerau, also completed both questionnaires.
RESULTS: A total of 11 questions (nine from the function domain and two from the pain domain) were eliminated, leading to the modified score consisting of 12 questions. Comparing the results of SACRAH and M-SACRAH, as well as the domain scores in individual patients, correlation coefficients were r = 0.978 for HOA patients (P < 0.0001) and r = 0.986 for RA patients (P < 0.0001).
CONCLUSION: M-SACRAH, the shortened and simplified version of the original SACRAH questionnaire, proved to be as reliable and as representative as SACRAH for hand status in individual HOA and RA patients.

Entities:  

Mesh:

Year:  2004        PMID: 15304674     DOI: 10.1093/rheumatology/keh360

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation.

Authors:  Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Allison C Stover; Janet R Abrams
Journal:  J Cancer Surviv       Date:  2010-05-08       Impact factor: 4.442

2.  Chinese Medicine Yishen Jiangu Granules () on Aromatase Inhibitor-Associated Musculoskeletal Symptoms.

Authors:  Xing Zhang; Nan Peng; Ming-Wei Yu; Gan-Lin Zhang; Xu Sun; Guo-Wang Yang; Chen Li; Lin Yang; Xiao-Min Wang
Journal:  Chin J Integr Med       Date:  2018-07-31       Impact factor: 1.978

3.  Assessment of hand functions in rheumatoid arthritis using SF-SACRAH (short form score for the assessment and quantification of chronic rheumatoid affections of the hands) and its correlation to disease activity.

Authors:  Harpreet Singh; Suresh Kumar; Paulomi Talapatra; Vikas Gupta; Sucharita Ray; Harish Kumar
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

4.  Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Authors:  Dawn L Hershman; Joseph M Unger; Katherine D Crew; Danielle Awad; Shaker R Dakhil; Julie Gralow; Heather Greenlee; Danika L Lew; Lori M Minasian; Cathee Till; James L Wade; Frank L Meyskens; Carol M Moinpour
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

5.  Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

Authors:  Jun J Mao; Carrie Stricker; Deborah Bruner; Sharon Xie; Marjorie A Bowman; John T Farrar; Brandon T Greene; Angela DeMichele
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

Review 6.  [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective].

Authors:  T Stamm; K Machold; D Aletaha; G Stucki; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

7.  Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper.

Authors:  Margreet Kloppenburg; Tanja Stamm; Iain Watt; Franz Kainberger; Tim E Cawston; Fraser N Birrell; Ingemar F Petersson; Tore Saxne; Tore K Kvien; Barbara Slatkowsky-Christensen; Maxime Dougados; Laure Gossec; Ferdinand C Breedveld; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2007-03-14       Impact factor: 19.103

8.  Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.

Authors:  Heather Greenlee; Katherine D Crew; Theresa Shao; Grace Kranwinkel; Kevin Kalinsky; Matthew Maurer; Lois Brafman; Beverly Insel; Wei Yann Tsai; Dawn L Hershman
Journal:  Support Care Cancer       Date:  2012-11-01       Impact factor: 3.603

9.  Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.

Authors:  Justin C Brown; Jun J Mao; Carrie Stricker; Wei-Ting Hwang; Kay-See Tan; Kathryn H Schmitz
Journal:  Breast J       Date:  2013-10-25       Impact factor: 2.431

10.  A comparison of the modified score for the assessment of chronic rheumatoid affections of the hands and the australian/canadian osteoarthritis hand index in hand osteoarthritis patients.

Authors:  Judith Sautner; Ingrid Andel; Bernhard Rintelen; Burkhard F Leeb
Journal:  Int J Rheumatol       Date:  2009-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.